Georg-August-University Göttingen (UMG) and MRC Technology (MRCT) have signed a collaboration agreement for the development of a novel therapy for neurodegenerative diseases based on an antibody that targets particular forms of amyloid beta peptides, amyloid beta 4-x. The aim is to develop a new antibody therapy for Alzheimer’s Disease (AD).
28 July 2015
BIA’s report, Celebrating UK bioscience, features UK bioscience successes. It incldes Keytruda, a new generation drug which uses the body’s immune system to fight cancer. It features MRC Technology’s role humanising the antibody. Read the article.
27 July 2015
Andrew Farquharson has been appointed Director of Technology Transfer from 1 September.
7 July 2015
Coombs, P., Ansell, K., Whalley, D., Jones, H., Mpamhanga, C., Osborne, S., Large, J., Smiljanic-Hurley, E., Harding, D., Visser, N., Pepper, D., Taylor, D. (2015), Fragment-based discovery and characterisation of inhibitors of the de novo purine biosynthetic enzyme PAICS. In Biophysics in Drug Discovery, Medicinal Chemistry, 9-12 June 2015, Strasbourg, France
23 June 2015
Funding worth nearly half a million pounds will unite academics at the University of Southampton with drug discovery experts at the medical research charity MRC Technology, to target the immune system in the hunt for new treatments for Alzheimer’s disease.
19 June 2015
Collaboration to assess the therapeutic potential in bone diseases of Peptinnovate’s unique peptides derived from the bacterium Mycobacterium tuberculosis.
10 June 2015
Poster prize for presentation at Chemistry in Health Conference
Ela Smiljanic-Hurley’s poster presentation at the Chemistry in Health Conference 2015, held on 26 May at the Royal Society of Chemistry, was voted best poster by conference delegates. View the poster here. Ela is a scientist in the Chemistry department at MRC Technology.
27 May 2015
Smiljanic-Hurley, E., Large, J.M., Merritt, A.T., Osborne, S.A., Ansell, K.H., Kettleborough, C.A., Whalley, D., Khan, S., Tickle, D.C., Bowyer, P., Stewart, L. Barker, D.A. (2015). Design and synthesis of imidazopyridine inhibitors of PfPKG, a malarial kinase. In Chemistry in Health 2015, 26 May 2015, London UK.
27 May 2015
Patel, S., Fernandes, C., Camelo, A., Brown, R., Bartlett, N.W., Johnson, S.L., Barlow, J., McKenzie, A., Matthews, D., (2015). A humanized anti-IL-17BR monoclonal antibody with wide therapeutic potential in allergic asthma, ulcerative colitis, pulmonary fibrosis and pancreatic cancer. In PEGS (Boston) Conference, 4-8 May 2015, Boston USA
19 May 2015
Brain health company IXICO launched a digital platform, Project Cygnus, to support patients with the diseases that cause dementia. IXICO is the lead partner in the project, working alongside MRC Technology, The Northern Health Science Alliance Network (NHSA) and several NHS Trusts in the North of England. The project is part-funded by Innovate UK (formerly the Technology Strategy Board).
30 April 2015